CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

Marmé, Frederik

CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. [electronic resource] - Breast cancer research and treatment Apr 2012 - 819-31 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1573-7217

10.1007/s10549-011-1759-9 doi


Amino Acid Substitution
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Breast Neoplasms--drug therapy
CD24 Antigen--genetics
Cell Line, Tumor
Cyclophosphamide--administration & dosage
Docetaxel
Doxorubicin--administration & dosage
Female
Genotype
Glutamates--administration & dosage
Guanine--administration & dosage
Humans
Leukocyte Common Antigens--metabolism
Lymphocytes--metabolism
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness
Pemetrexed
Polymorphism, Genetic
Sequence Analysis, DNA
Statistics, Nonparametric
Taxoids--administration & dosage
Treatment Outcome